Mark H F, Bier J A, Scola P
Laboratory of Cytogenetics, FISH, and Genotoxicology, Rhode Island Hospital, Providence 02903, USA.
Ann Clin Lab Sci. 1996 Jul-Aug;26(4):323-8.
The present paper summarizes our existing database on chromosomal abnormalities found in patients referred because of a question of the Fragile X Syndrome during the period from January 1, 1990 to June 30, 1995. Cytogenetic results were derived from testing performed at the cytogenetics laboratory at Rhode Island Hospital. All positive fragile X individuals detected among our sample population represent index patients from separate kindreds. Of a total of 327 cases referred for fragile X testing, 10 (3.06 percent) were found to be positive for fragile X by either cytogenetics alone or by both cytogenetics and DNA testing, 12 (3.60 percent) were found to be positive for either a numerical or structural chromosomal abnormality, while 10 (3.06 percent) were found to exhibit a heteromorphism. Positive chromosomal findings included numerical chromosomal abnormalities of the sex chromosomes and autosomes, deletions, and translocations. Heteromorphism mostly involved an increase in the length of heterochromatic regions of certain chromosomes as well as a pericentric inversion of a chromosome 9, usually considered normal variants. It is concluded that chromosomal abnormalities other than fragile X are found with equal and, in some cases, higher frequency than the frequency of fragile X positivity in patients referred for a question of the Fragile X Syndrome. Our figures, consistent with those reported in the literature, underscore the value of routine karyotyping in this population of patients. Except under special circumstances, it is important that GTG-banding analysis be performed so that the entire human genome be examined in addition to scoring for the fragile X mutation on Xq27.3. Especially in view of the recent finding of the relative rarity of this condition, the exclusive use of DNA analysis is not advised.